1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Endometrial cancers

Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Technology appraisal guidance [TA779] Published: 16 March 2022

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Tools and resources

Tools to help you put the guidance into practice.

Resource impact

  • Resource impact statement  

Education

  • Managed access agreement PDF 411 KB 16 March 2022  

Guidance into practice

  • About the Into practice guide  
  • Practical steps to improving the quality of care and services using NICE guidance